Michelle Glass

11.7k total citations · 2 hit papers
142 papers, 8.9k citations indexed

About

Michelle Glass is a scholar working on Pharmacology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Michelle Glass has authored 142 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Pharmacology, 98 papers in Cellular and Molecular Neuroscience and 48 papers in Molecular Biology. Recurrent topics in Michelle Glass's work include Cannabis and Cannabinoid Research (112 papers), Neurotransmitter Receptor Influence on Behavior (57 papers) and Neuroscience and Neuropharmacology Research (48 papers). Michelle Glass is often cited by papers focused on Cannabis and Cannabinoid Research (112 papers), Neurotransmitter Receptor Influence on Behavior (57 papers) and Neuroscience and Neuropharmacology Research (48 papers). Michelle Glass collaborates with scholars based in New Zealand, United States and Australia. Michelle Glass's co-authors include Richard L. M. Faull, Christian C. Felder, Mike Dragunow, Mark Connor, Natasha L. Grimsey, John C. Ashton, John K. Northup, John M. McPartland, David B. Finlay and Samuel D. Banister and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Michelle Glass

140 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

1997 807 citations Michelle Glass et al. profile →
Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a G_sLinkage to the CB1 Receptor

1997 513 citations Michelle Glass et al. profile →

Peers

Michelle Glass

PHARM

CMN

TOXIC

Mary E. Abood United States

Lesley Stevenson United Kingdom

Ruth A. Ross United Kingdom

Aviva Breuer Israel

Nephi Stella United States

William A. Devane United States

Andrea G. Hohmann United States

Daniela Parolaro Italy

Zvi Vogel Israel

Jorge Manzanares Spain

Mary E. Abood United States

Michelle Glass

6.7k ×1.0

PHARM

4.5k ×0.9

CMN

2.7k ×1.4

854 ×0.7

TOXIC

1.1k ×1.0

Citations per year, relative to Michelle Glass Michelle Glass (= 1×) peers Mary E. Abood

Countries citing papers authored by Michelle Glass

Since Specialization

Citations

This map shows the geographic impact of Michelle Glass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Glass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Glass more than expected).

Fields of papers citing papers by Michelle Glass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Glass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Glass. The network helps show where Michelle Glass may publish in the future.

Co-authorship network of co-authors of Michelle Glass

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Glass. A scholar is included among the top collaborators of Michelle Glass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Glass. Michelle Glass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Liang, et al.. (2023). A kinetic model for positive allosteric modulator (PAM)‐antagonists for the type 1 cannabinoid (CB₁) receptor. British Journal of Pharmacology. 180(20). 2661–2676. 3 indexed citations

Patel, Monica, Natasha L. Grimsey, Samuel D. Banister, David B. Finlay, & Michelle Glass. (2023). Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB₂ receptor. Pharmacology Research & Perspectives. 11(6). e01157–e01157. 7 indexed citations

Daldegan‐Bueno, Dimitri, Lucas Oliveira Maia, Michelle Glass, Didier Jutras‐Aswad, & Benedikt Fischer. (2021). Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies. Psychopharmacology. 239(5). 1211–1230. 10 indexed citations

Cairns, Elizabeth A., Katharina Elisabeth Grafinger, Annelies Cannaert, et al.. (2021). NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. ACS Chemical Neuroscience. 12(21). 4020–4036. 8 indexed citations

Cairns, Elizabeth A., Richard C. Kevin, Felcia Lai, et al.. (2021). Structure–activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC Medicinal Chemistry. 13(2). 156–174. 21 indexed citations

Braund, Rhiannon, et al.. (2020). Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre. Clinical Toxicology. 59(6). 472–479. 10 indexed citations

Zhu, Xiao, David B. Finlay, Michelle Glass, & Stephen B. Duffull. (2020). Evaluation of the profiles of CB₁ cannabinoid receptor signalling bias using joint kinetic modelling. British Journal of Pharmacology. 177(15). 3449–3463. 14 indexed citations

Zhu, Xiao, David B. Finlay, Michelle Glass, & Stephen B. Duffull. (2019). An intact model for quantifying functional selectivity. Scientific Reports. 9(1). 5 indexed citations

Zhu, Xiao, David B. Finlay, Michelle Glass, & Stephen B. Duffull. (2019). Model‐free and kinetic modelling approaches for characterising non‐equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB₁ receptors. British Journal of Pharmacology. 176(14). 2593–2607. 22 indexed citations

10.

Zhu, Xiao, David B. Finlay, Michelle Glass, & Stephen B. Duffull. (2018). An evaluation of the operational model when applied to quantify functional selectivity. British Journal of Pharmacology. 175(10). 1654–1668. 15 indexed citations

11.

Banister, Samuel D., Axel Adams, Richard C. Kevin, et al.. (2018). Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold‐ hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA. Drug Testing and Analysis. 11(2). 279–291. 47 indexed citations

12.

MacDonald, Christa, et al.. (2014). Development of positive control tissue for in situ hybridisation using Alvetex scaffolds. Journal of Neuroscience Methods. 238. 70–77. 3 indexed citations

13.

Grimsey, Natasha L., Catherine E. Goodfellow, Mike Dragunow, & Michelle Glass. (2011). Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1813(8). 1554–1560. 67 indexed citations

14.

Angel, Catherine E., et al.. (2011). Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology. Journal of Neuroscience Methods. 200(2). 173–180. 48 indexed citations

15.

Glass, Michelle, et al.. (2007). Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. British Journal of Pharmacology. 152(5). 583–593. 207 indexed citations

16.

Glass, Michelle, Jiwon Hong, Timothy A. Sato, & Murray D. Mitchell. (2005). Misidentification of prostamides as prostaglandins. Journal of Lipid Research. 46(7). 1364–1368. 34 indexed citations

17.

Kearn, Christopher S., et al.. (2005). Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Enhances Heterodimer Formation: A Mechanism for Receptor Cross-Talk?. Molecular Pharmacology. 67(5). 1697–1704. 284 indexed citations

18.

McPartland, John M. & Michelle Glass. (2001). Nematicidal effects of hemp ( Cannabis sativa ) may not be mediated by cannabinoid receptors. New Zealand Journal of Crop and Horticultural Science. 29(4). 301–307. 20 indexed citations

19.

McPartland, John M., Vincenzo Di Marzo, Luciano De Petrocellis, Alison R. Mercer, & Michelle Glass. (2001). Cannabinoid receptors are absent in insects. The Journal of Comparative Neurology. 436(4). 423–429. 80 indexed citations

20.

Glass, Michelle & John K. Northup. (1999). Agonist Selective Regulation of G Proteins by Cannabinoid CB1 and CB2 Receptors. Molecular Pharmacology. 56(6). 1362–1369. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact